LMR Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

LMR Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.39M	Buy	+50,000	New	+$6.24M	0.01%	564
2025 Q1	–	Sell	-175,000	Closed	-$15.8M	–	1666
2024 Q4	$15.8M	Buy	175,000 +125,000	+250%	+$12.1M	0.13%	155
2024 Q3	$4.94M	Sell	50,000 -149,300	-75%	-$14.7M	0.04%	369
2024 Q2	$18.5M	Buy	+199,300	New	+$17.9M	0.16%	124
2024 Q1	–	Sell	-200,200	Closed	-$17.9M	–	1332
2023 Q4	$17.9M	Sell	200,200 -180,000	-47%	-$13.4M	0.2%	118
2023 Q3	$27.8M	Hold	380,200	–	–	0.31%	68
2023 Q2	$31.6M	Buy	+380,200	New	+$31.8M	0.35%	61

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LMR Partners's XBI Position: Q1 2026 in Review

LMR Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 93% in Q1 2026, selling an estimated $34.7M and leaving 20,700 shares worth $2.64M. The position accounts for 0.01% of the portfolio, ranked #799.

LMR Partners first reported a position in XBI in Q2 2021 and has held it in 14 quarters since. The position peaked at $69.4M in Q2 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

LMR Partners held 20,700 shares of State Street SPDR S&P Biotech ETF worth $2.64M as of Q1 2026.
LMR Partners sold 277,947 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $34.7M.
State Street SPDR S&P Biotech ETF made up 0.01% of LMR Partners's portfolio in Q1 2026, its #799 holding.
LMR Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 14 quarters since.
LMR Partners's State Street SPDR S&P Biotech ETF position peaked at $69.4M in Q2 2022.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.